Princeton, NJ ― Princeton University's Office of Technology Licensing is pleased to announce the appointment of a new Executive in Residence (XIR), Mahmoud Mahmoudian, who will be available to provide advice to faculty, students and staff who have discoveries in the life sciences that could be applied to solve critical health challenges and improve clinical outcomes.
Dr. Mahmoudian’s career spans 20 years in the biotechnology, pharmaceutical and chemical sectors. He joined Ferring Pharmaceuticals in 2012 as Vice President, Head of Innovative Medicines to build its future R&D pipeline in immunotherapy.
Prior to that, he was at Merck leading the company's External Research and R&D Operations in vaccines, biologics and biosimilars (Merck BioVentures) on a global basis. At Dow he was the Global Head of Biotechnology overseeing all of research and strategic alliances in five sites (US, UK, France, China, Japan).
Dr. Mahmoudian was recruited to Eastman earlier in his career as the Worldwide Head of Biotechnology responsible for R&D, partnering, managing growth and development of its BioProducts portfolio.
Dr. Mahmoudian’s career spans 20 years in the biotechnology, pharmaceutical and chemical sectors. He joined Ferring Pharmaceuticals in 2012 as Vice President, Head of Innovative Medicines to build its future R&D pipeline in immunotherapy.
Prior to that, he was at Merck leading the company's External Research and R&D Operations in vaccines, biologics and biosimilars (Merck BioVentures) on a global basis. At Dow he was the Global Head of Biotechnology overseeing all of research and strategic alliances in five sites (US, UK, France, China, Japan).
Dr. Mahmoudian was recruited to Eastman earlier in his career as the Worldwide Head of Biotechnology responsible for R&D, partnering, managing growth and development of its BioProducts portfolio.
He began his career at GlaxoSmithKline, where he held a variety of research, technology and management roles of increasing responsibility in drug discovery, preclinical development and BioPharm R&D.
Dr. Mahmoudian has extensive scientific and operations experience leading multi-national teams in R&D (discovery, preclinical, phase I-III), Chemistry, Manufacturing and Control (CMC), tech transfer, GMP biomanufacturing and the licensure of six "blockbuster" therapies.
Dr. Mahmoudian earned his Ph.D. in Biotechnology from Imperial College at the University of London. He serves on the advisory boards of several startups and universities and is a board member of the European Federation of Biotechnology. Dr. Mahmoudian is an elected Fellow of the Royal Society of Chemistry (FRSC) and has 60 publications and patents to his name.
"We are very fortunate to have a successful scientist and executive with Mahmoud Mahmoudian’s experience and enthusiasm for working with academic researchers with us," said John Ritter, director of the Office of Technology Licensing. "Mahmoud's background in life science provides us with additional domain expertise in an important area of research for Princeton."
Dr. Mahmoudian said he looks forward to his new role as XIR. "I am delighted to be able to serve as an Executive in Residence to guide Princeton University faculty who wish to externalize their discoveries and research inventions, bringing innovative medicines to patients with high unmet medical needs," he said.
Dr. Mahmoudian will be located in the Office of Technology Licensing, 87 Prospect Avenue, 3rd Floor, and will be available to meet with faculty, staff, postdoctoral researchers, graduate students and undergraduates who have questions about making their discoveries available for further development.
He will be on campus approximately one day a week. To arrange a meeting with Dr. Mahmoudian or our continuing XIRs, Rakefet (Kef) Kasdin and Joseph Studholme, those in the University community should contact their Office of Technology Licensing associate or email Tony Williams at anthonyw@princeton.edu.
Dr. Mahmoudian has extensive scientific and operations experience leading multi-national teams in R&D (discovery, preclinical, phase I-III), Chemistry, Manufacturing and Control (CMC), tech transfer, GMP biomanufacturing and the licensure of six "blockbuster" therapies.
Dr. Mahmoudian earned his Ph.D. in Biotechnology from Imperial College at the University of London. He serves on the advisory boards of several startups and universities and is a board member of the European Federation of Biotechnology. Dr. Mahmoudian is an elected Fellow of the Royal Society of Chemistry (FRSC) and has 60 publications and patents to his name.
"We are very fortunate to have a successful scientist and executive with Mahmoud Mahmoudian’s experience and enthusiasm for working with academic researchers with us," said John Ritter, director of the Office of Technology Licensing. "Mahmoud's background in life science provides us with additional domain expertise in an important area of research for Princeton."
Dr. Mahmoudian said he looks forward to his new role as XIR. "I am delighted to be able to serve as an Executive in Residence to guide Princeton University faculty who wish to externalize their discoveries and research inventions, bringing innovative medicines to patients with high unmet medical needs," he said.
Dr. Mahmoudian will be located in the Office of Technology Licensing, 87 Prospect Avenue, 3rd Floor, and will be available to meet with faculty, staff, postdoctoral researchers, graduate students and undergraduates who have questions about making their discoveries available for further development.
He will be on campus approximately one day a week. To arrange a meeting with Dr. Mahmoudian or our continuing XIRs, Rakefet (Kef) Kasdin and Joseph Studholme, those in the University community should contact their Office of Technology Licensing associate or email Tony Williams at anthonyw@princeton.edu.
